Sab there is lots to like at Anavex despite the brutal failure to de-risk their clinical programs. Missling admitted the company screwed up last year at the AGM and indicated they had learned their lesson.
I am not counting on it, but it is possible that the appeal is part of the expected process. Let's see.
JPM is just a conference. I have been a few times and it is pro forma. No big deal either way.